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ㅋ
Irritable bowel syndrome (IBS) has been one of the commonly presented gastrointestinal disorders. It is of interest how com-
monly it presents in the society. Western studies indicated that most population-based IBS prevalences range 10%-15%. It is 
believed that IBS is prevalent in both East and West countries without a significant prevalence difference. Most recently, the 
Asia IBS prevalence has a higher trend in the affluent cities compared to South Asia. Since many Asia IBS prevalence studies 
have been published in the recent decade, we could compare the IBS prevalence data divided by various criteria in looking 
whether they were also comparable to this of West community. Summarized together, most Asia community IBS prevalences 
based on various criteria are usually within the range 1%-10% and are apparently lower than these of selected populations. 
Within the same population, the prevalence orders are first higher based on Manning criteria, then followed by Rome I criteria 
and finally reported in Rome II criteria. Overall, the median value of Asia IBS prevalences defined by various criteria ranges 
6.5%-10.1%. With regard to gender difference, female predominance is usually found but not uniquely existed. For the IBS 
subtypes, the proportions of diarrhea predominant-IBS distribute widely from 0.8% to 74.0%, while constipation predom-
inant-IBS proportion ranges 12%-77%. In conclusions, current Asia IBS prevalence is at least equal to the Western countries. 
Female predominant prevalence in Asia is common but not uniquely existed, while the proportions of IBS subtypes are too var-
iable to find a rule. 
(J Neurogastroenterol Motil 2010;16:389-400)
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Introduction
Upon Rome III definition, irritable bowel syndrome (IBS) 
has been a biopsychosocial dysfunction. It means that a biological 
bowel dysfunction is the final result of brain-gut linkage and 
modified by the social, environmental and psychological 
factors.
1,2 Since a well-known functional disorder usually coex-
isted with other somatic complaints, IBS per se has an obvious im-
pact on living and quality of life of sufferers leading to the ex-
cessive social costs for medical seeking behavior and absen-
teeism.
3-9 Today, IBS has been included as one of the commonly 
presented functional gastrointestinal disorders (FGIDs).
1 It is of 
interest how commonly it presents in the society. In addition, 
knowing the IBS prevalence may estimate how it would consume 
the limited medical resources in the society. Western studies in-
dicated that the population-based IBS prevalence widely ranges 
between 3%-20%, whereas the most reported data range from Full-Young Chang, et al
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10% to 15%.
10,11 It draws a controversy why the IBS prevalence 
studies usually show an obvious discrimination. Actually, most 
prevalence study obtained data completely depend upon the re-
sponse of distributed questionnaires to the studied subjects. 
Thereafter, the demographic characteristics in terms of evaluated 
population, willing of responsiveness, geographical location, cri-
teria to define, etc always individually exist leading to the study 
heterogeneity and variation in the reported IBS prevalences.
12-14 
Of them, the employed IBS diagnostic criteria may obtain ex-
tremely distinct results for the same population. For example, 
Manning definition often yields a higher value compared to this 
of either Rome I or II definition with a gap of 2-5 folds or 
2.5%-37.0%.
4,14 Even confined to the Manning definition, the 
number of used disorders results in different values.
14 In addi-
tion, large-scaled and questionnaire-based prevalence study does 
not exclude the alarm symptoms and the obtained results are un-
likely to reflect the true IBS manifestations seen clinically.
4,15,16 
Since a characteristically biopsychosocial disorder, many social 
and cultural factors indeed have an apparent impact on the mean-
ing, expression and course of FGIDs including IBS.
17 Accordin-
gly, gender,
18-22 age,
23,24 economic state,
24-31 education level,
24-29 mar-
ried state,
25,28,31 food,
29-32 race,
33 stress,
21,22,28,31,34-36 climate,
29,31 drugs,
35 
dysentery history
29,35 and coexisted dyspepsia
37 etc all have been 
addressed to be the risk factors leading to IBS.
Unfortunately, it is very hard to define that all enrolled study 
populations throughout the world should be harmonized with a 
least heterogeneity. Thus obtained IBS prevalences throughout 
the world would be quite variable among the studies. Besides, it is 
unknown whether these mentioned factors are truly existed be-
cause prevalence studies do not attempt to confirm their 
existence. Even some studies indicate the contradictory impact on 
the IBS. For instance, the same questionnaire applied to different 
countries may obtain the very dissimilar prevalence results, such 
as this conducted in Thailand and Western countries,
38 another 
conducted in USA and 8 European countries
39,40 and an early 
study carried out in Japan and The Netherlands,
41 respectively. 
With regard to the IBS prevalence around the world, it has been 
indicated that the IBS prevalence is lower in non-western 
countries.
17 In addition, a study based on Manning criteria in-
dicated that the IBS prevalence of USA Asian residents was low-
er compared to others.
42 However, this early statement meets 
challenge. Likewise, IBS prevalence is reported as higher as 
26%-33% in the selected populations of the African countries.
23,43 
Similarly, the Japanese IBS prevalence was almost 3-fold of this 
of Dutch using the same questionnaire.
41 Kang
44 compared East 
IBS prevalences to those of West counterparts and provided the 
median values of 12% vs 17% in Manning criteria, 10.4% vs 
9.2% in Rome I and 7.6% vs 6.0% in Rome II, respectively. He 
finally concluded no convincing prevalence difference existed in 
the East and West countries. In the same year, Gwee et al
45 be-
lieved that the IBS prevalence is increasing among the Asia coun-
tries with the estimated community prevalence ranging 5.7%-8.6%, 
whereas these of selected population reach up to 16%-45%. Most 
recently, he reviewed the Asia IBS studies and indicated that the 
Asia IBS prevalence has a trend of higher in the affluent cities 
compared to South Asia, eg, 8.6%-9.8% vs 4.2%.
46 Talley
4 also 
pointed out that IBS is prevalent in both East and West countries 
without necessarily to emphasize on the prevalence difference. 
With regard to study IBS prevalence, employed criteria should 
be considered since it may produce enormously different re-
sults.
47,48 While the proportions of IBS subtypes may not corre-
late well between the used criteria.
49,50 Nevertheless, it is believed 
that no consistent differences in sensitivity and specificity be-
tween various criteria to diagnose IBS clinically.
51 Very recently, 
many Asia IBS prevalence studies have been published within 
this decade. Now we could compare the IBS prevalence data div-
ided by various criteria in looking whether they were also com-
parable to this of West community. 
Community Population Based IBS 
 Prevalences of Western Developed 
 Countries
Hungin et al
40 had conducted a large-scaled study that evenly 
enrolled population sizes of UK, 5999; France, 5033; Germany, 
5002; Italy, 5082; Holland, 5463; Belgium, 5229; Spain, 5097 
and Switzerland, 5079, respectively. Their study indicated that 
the recommended Rome criteria obtained a value less than 5%, 
whereas the extreme variation of prevalence values among en-
rolled countries still existed, eg, 11.7% in Italy and only 1.7% in 
German. Besides, Manning criteria defined IBS prevalence was 
higher compared to those of 2 Rome definitions within the same 
population. In order to know what is the most reported pop-
ulation based IBS prevalence, Table 1 illustrates 25 commun-
ity-based IBS prevalences of Latin America and Western devel-
oped countries ranging from Europe, North America to 
Australia. Overall, 5 of 11 Manning and other criteria defined 
prevalence data are less than 10.5%, whereas remaining 6 values 
are higher than this point. In addition, 14 of 21 Rome defined 
prevalences are within the range 2%-10%, whereas another 7 Asia IBS Prevalence 
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Table 1. Community Population Based Prevalences of Irritable Bowel Syndrome Among the Western Developed Countries and Latin 
America
Author Year of publication  Country Sample size Prevalence  (Used criteria) M/F ratio
Hungin
40 2003 8 European countries 41,984   6.8% (Any) 1/1.69 (NM)
                                         6.5% (Manning)
                                                                        4.2% (Rome I)
                                         2.9% (Rome II)
Vandvik
19 2006 Norway 4,622   8.4% (Rome II) 1/1.56 
Agréus
52 1995 Sweden 1,156 12.5%  (NM) ND
Hillilä
14 2004 Finland 3,650 16.2% (Manning X2) 1/1.47 (M X2)
                                         9.7% (Manning X3) 1/1.35 (M X3)
                                         5.6% (Rome I) 1/1.10 (Rome I)
                                         5.1% (Rome II) 1/1.04 (Rome II)
Hillilä
9 2010 Finland 3,650 15.9% (Manning) 1/1.50
                                         5.1% (Rome II) 1/1.10
Jones
53 1992 UK 1,620 22.0% (Manning) 1/1.38 
Kennedy
20 2000 UK 3,169 17.2% (Manning) 1/2.20
Wilson
54 2004 UK 4,807 10.5% (Rome II) 1/2.12 
Bommelaer
55 2004 France  8,221   2.5% (Manning) 1/1.82 (Manning)
                                         2.1% (Rome I) 1/2.00 (Rome I)
                                         1.1% (Rome II) 1/1.44 (Rome II)
Dapoigny
56 2004 France 20,000   4.7% (Rome II) 1/1.54 
Mearin
47 2001 Spain 2,000 10.3% (Manning) 1/2.63
                                       12.1% (Rome I) 1/2.33
                                         3.3% (Rome II) 1/2.42
Corazziari
57 2008 Italy 29,139   7.4% (NM) 1/1.95 
Zagari
58 2010 Italy 1,033   7.1% (Rome II) ND
Katsinelos
59 2009 Greece 2,397 15.7% (Rome II) 1/1.31
Andrews
25 2005 USA 25,986   6.6% (Rome II) 1/1.82 
Hungin
39 2005 USA 5,009 10.4% (Manning) 1/1.44 (Manning)
                                         7.9% (Rome I) 1/1.38 (Rome I)
                                         6.7% (Rome II) 1/1.36 (Rome II)
Minocha
60 2006 USA 1,000   9.5% (Rome II) NS (ND)
Choung
61 2007 USA 2,298   4.4% (Rome II) ND
Jung
62 2010 USA 1,695 13.2% (Rome II) 1/1.93
Thompson
63 2002 Canada 1,198 13.5% (Rome I) 1/2.13 (Rome I)
                                       12.1% (Rome II) 1/1.74 (Rome II)
Li
18 2003 Canada 437 25.2% (Rome II) 1/1.88
Valerio-Ureña
64 2010 Mexico 459 16.9% (Rome II) 1/1.96
Gómez Alvarez
65 2009 Colombia 558 19.9% (Rome III) ND
Boyce
34 2000 Australia 2,910 13.6% (Manning) 1/1.89 (Manning)
                                         4.4% (Rome I) 1/3.10 (Rome I)
                                           6.9% (Rome II) 1/2.19 (Rome II)
Boyce
66 2006 Australia 　762   4.4% (Rome I) 1/2.98 (Rome I)
                                       8.9% (Rome II) 1/1.37 (Rome II)
X2, 2 diagnostic statements; X3, 3 diagnostic statements; M/F, male/female; ND, no data; NM, not mentioned; NS, not significant.
prevalence data are higher than 10% particularly a Canadian 
study based on small sample size.
18 Secondly, Manning criteria 
based studies usually report a higher prevalence than this of 
Rome definition within the same population. Thirdly, the same 
country using the same criteria may obtain different values 
among various enrolled community populations. Fourthly, 
small-scale study often results in a higher IBS prevalence even 
based on community population. Finally, female predominance is 
invariably found no matter of used IBS definitions.Full-Young Chang, et al
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Table 2. Prevalences of Manning and Other Criteria Defined Irritable Bowel Syndrome in Asia Countries
Year of  Prevalence 
Author Country Sample size Study type M/F ratio
publication (Used  criteria)
Massarrat
67 1995 Iran 947 Selected   3.2% (NM) NM
Shah
68 2001 India 2,549 Community   7.5%  NM
Ghoshal
69 2008 India 4,500 Community   4.2% (NM) 1/0.93
Danivat
38 1988 Thailand 912 Selected   4.4% (NM) NM
Ho
70 1998 Singapore 696 Community   2.3% (Local) M = F (ND)
Chen
71 2000 Singapore 271 Community   3.2% (NM) 1/1.13
Gwee
24 2004 Singapore 2,276 Community 11.0% 1/1.33 
Lau
72 2002 Hong Kong 1,298 Community 10.0% NM 
Pan
29 2000 China 2,486 Community     7.3% 1/1.15 
Xiong
35 2004 China 4,178 Community 11.5% 1/1.34 
Schlemper
41 1993 Japan 231 Selected 25.0% 1/1.35
M/F, male/female; ND, no data; NM, not mentioned.
Table 3. Prevalences of Rome I and α Criteria Defined Irritable Bowel Syndrome in Asia Countries
Year of 
Author Country Sample size Study type Prevalence M/F ratio
publication 
Zuckerman
73 2006 Vietnam 411 Selected   7.20% 1/1.92
Tan
36 2003 Malaysia 533 Selected 15.80% 1/1.59
Gwee
24 2004 Singapore 2,276 Community 10.40% 1/1.30
Lau
72 2002 Hong Kong 1,298 Community   6.00% NM 
Cheung
74 2007 Hong Kong 1,649 Community   4.00% M = F (ND)
Pan
29 2000  China 2,486 Community   0.82% NM 
Lu
75 2003 Taiwan 2,018 Selected 17.50% NM 
Kim
30 2005 Korea 1,717 Selected   5.70% (Rome α) 1/1.27 
Kawamura
76 2001 Japan 2,263 Selected   6.50% NM
M/F, male/female; ND, no data; NM, not mentioned.
IBS Prevalences of Asia Countries
Table 2 provides 11 IBS prevalence data of Asia countries. 
Of them, 6 were based on Manning definition, whereas 5 did not 
mention their employed definitions. Most reported prevalences 
are within the range 2.3%-11.5% but a Japanese study based on 
selected population obtained a higher value.
41 Apart from other 
definitions, the median value of 6 Manning based studies is 10%. 
Female predominance is found but not always existed. Based on 
Rome I criteria definition, Table 3 depicts 8 Asia IBS prevalence 
data plus another Korea study from Rome α definition. Many of 
them were conducted in East Asia. The range of 4 community 
population based prevalences is within 0.82%-10.4%, whereas 
the data of 5 selected population studies are variable from over-
lapping to much higher. The median value of 8 Rome I definition 
based studies is 6.5%. Female predominance remains existed. 
Rome II criteria based prevalence has been extensively reported 
in Asia, Table 4 provides 35 IBS prevalence values obtained as 
far as from Turkey to the most Eastern Asia countries such as 
Japan and Korea. Overall, 14 of 16 community population based 
prevalences are within 2.9% and 10.2%, whereas another 2 values 
are higher up to about 14.0%.
82,86 With regard to 19 data of se-
lected population studies, only 7 values are less than 10.0%, 
whereas other 12 higher values even reach up to 31.0%.
97 Overall, 
the median value of 35 Rome II definition based studies is 8.6%. 
Regarding the gender difference based on Rome II criteria, 22 of 
31 studies reported a female predominance, whereas 5 reported 
male predominance and 4 reported almost equally distributed. 
Table 5 provides 9 Rome III criteria defined IBS prevalence data 
among the Asia countries. Two West Asia community-based 
studies indicate the values of 1.1% and 11.4%, respectively.
26,101 Asia IBS Prevalence 
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Table 4. Prevalences of Rome II Criteria Defined Irritable Bowel Syndrome in Asia Countries
Author Year of publication  Country Sample size Study type Prevalence M/F ratio
Sperber
26 2007 Israel 1,000 Community   2.9%  1/2.06
Celebi
27 2004 Turkey 1,766 Selected   6.3%  1/1.48
Yilmaz
77 2005 Turkey 3,000 Community 10.2% 1/1.55
Basaranoglu
78 2008 Turkey 707 Selected   8.6%  M = F (ND)
Hoseini-Asi
79 2003 Iran 4,726 Community   5.8%  1/1.17
Sohrabi
80 2010 Iran 1,436 Selected   4.1% 1/2.19
Yarandi
81 2010 Iran 6,476 Selected 21.9% 1/1.58
Jafri
82 2007 Pakistan 1,167 Community 14.0%  M > F (ND)
Husain
28 2008 Pakistan 880 Selected 13.3% 1/1.02
Masud
83 2001 Bangladesh 2,426 Community   8.5%  1/1.84
Perveen
84 2009 Bangladesh 1,503 Community   7.7% 1/1.28
Devanarayana
85 2010 Sri Lanka 427 Selected   2.8%  NM
Rajendra
86 2004 Malaysia 949 Community 15.6% 1/1.40
Gwee
24 2004 Singapore 2,276 Community   8.6%  1/1.21 
Lau
72 2002 Hong Kong 1,298 Community   3.6% 1/1.06 
Kwan
87 2002 Hong Kong 1,000 Community   6.6%  1/1.30
Lee
88 2009 Hong Kong 2,005 Community   5.4% 1/1.35
Xiong
35 2004 China 4,178 Community   5.7%  1/1.25 
Dong
31 2005 China 5,403 Selected 13.8% 1/1.80
Wang
89 2007 China 3,014  Selected 18.5%  M = F (ND)
Dai
90 2008 China 1,147 Selected   4.7%  1/1.34
Shen
91 2009 China 491 Selected 15.7% 1/1.16
Zhao
92 2010 China 16,091 Community   4.6% 1/1.22
Lu
75 2003 Taiwan 2,018 Selected 22.1% 1/0.64, NS
Han
32 2006 Korea 1,066 Community   6.6%  1/0.85
Park
21 2008 Korea 1,124 Selected 16.8% 1/1.36
Lee
93 2009 Korea 1,443 Selected   9.6% NM
Son
94 2009 Korea 405 Selected 25.7% Only enrolled girls
Park
95 2010 Korea 1,009 Community   8.0% 1/1.50
Kumano
22 2004 Japan 4,000 Community   6.1%  1/1.73
Shiotani
96 2006 Japan 2,495 Selected 10.7% 1/2.04
Shinozaki
97 2008 Japan 633 Selected 31.0% 1/1.24
Hori
98 2009 Japan 181 Selected 22.1% NM
Okumura
99 2010 Japan 5,813 Selected   1.2% 1/0.92
Kaji
100 2010 Japan 2,680 Selected 14.2% NM
M/F, male/female; ND, no data; NM, not mentioned; NS, not significant.
A Korea community study provides prevalence of 9.0%,
98 where-
as 6 selected population based studies are very variable ranging 
7.0%-21.9%. The median value of 9 Rome III definition based 
studies is 10.1%. Female predominance is also found among 7 
reports. 
Summarized together, the reported IBS prevalences of Tables 
2-5 are very variable with a range 0.82%-31.0% among the Asia 
countries. However, these data are likely to indicate that the most 
Asia community prevalences are within the range 1%-10% and 
lower than these of selected populations as well as previous 
comments.
45,105,106 Similar to Table 1, the same country using the 
same criteria usually yields dissociated results among the differ-
ent study populations. On the other hand, the same population al-
ways results in different prevalences defined by various criteria. 
Within the same population, the prevalence orders are usually 
first higher based on Manning criteria, then followed by Rome I 
criteria and finally reported in Rome II criteria. This ranking 
characteristic is also to agree with Asia consensus.
106 Occasional-
ly, few studies in Asia and developed countries contradictorily in-
dicated the higher value based on Rome II than Rome I.
34,75  With 
regard to Rome III criteria, it is apparently higher than Rome II 
reported in Israeli, Chinese and Korean studies, respectively,
26,90,95 Full-Young Chang, et al
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Table 5. Prevalences of Rome III Defined Irritable Bowel Syndrome in Asia Countries
Year of 
Author Country Sample size Study type Prevalence   M/F ratio
publication 
Sperber
26 2007 Israel 1,000 Community 11.4% 1/1.37 
Khoshkrood-Mansoori
101 2009 Iran 18,180 Community   1.1% 1/2.31
Yarandi
81 2010 Iran 6,476 Selected 21.9% 1/1.58
Devanarayana
85 2010 Sri Lanka 427 Selected   7.0%  1/1.15
Dai
90 2008 China 1,147 Selected 10.4% 1/1.85
Wang
102 2008 China 3,014 Selected 15.9% 1/1.17
Park
95 2010 Korea 1,009 Community   9.0% 1/1.57
Nam
103 2010 Korea 4,296 Selected   9.1% 1/1.04
Noh
104 2010 Korea 2,388 Selected 10.1% NM
M/F, male/female; NM, not mentioned.
whereas another study carried out in a selected Chinese pop-
ulation showed comparable in both definitions.
89,102 In contrast, 
an Iran study yields a much lower prevalence by way of Rome III 
criteria.
101 Most importantly, the IBS prevalence studies con-
ducted on multi-ethnic countries such as Malaysia and Singapore 
clearly pointed out no difference existed among various ethnic 
populations.
24,36,70,86 Similarly, the IBS prevalence of Chinese mi-
nority was not different from this of Han ethnic.
31 Based on these 
observations and comparisons, we as well as the Asia consensus
106 
are strongly to conclude that the current Asia IBS prevalence is at 
least equal to the Western countries. 
Gender Difference of Asia Countries
Gender factor may play an impact on the FGIDs including 
IBS. As previously indicated that female gender has been one of 
factors leading to IBS and females usually report more FGID 
symptoms.
63 Perhaps it means that the visceral perception is de-
termined by the sex.
17 Female IBS subjects also have lower au-
thority over decisions at work.
107 Besides, Caucasian females easi-
ly suffer from IBS symptoms compared to males or African 
American females.
33 Based on the current IBS diagnostic criteria, 
higher positive predictive value is often obtained for females, 
whereas a negative predictive value exists for males.
108 Accordin-
gly, it is unknown whether these gender-related specificities ac-
count for the female predominance in many IBS studies. 
Clinically, constipation predominant IBS (C-IBS) is commonly 
seen among the females, whereas males usually manifest diar-
rhea-predominant IBS (D-IBS).
19,25,90,109,110 In addition, IBS is 
common among the Vietnamese females but no significant gen-
der effect on some bowel symptoms in terms of stool frequency, 
consistency and bloating is observed.
73 Table 1 depicts the IBS 
male/female ratio among the developed countries. Almost all ex-
cept a USA study indicate the female predominance, irre-
spectively of used criteria.
60 Interestingly, a Finnish study 
showed female predominance in Manning definition and gradu-
ally became equal in Rome II definition.
14 For the African IBS, 
female predominance is not reported yet.
23,43 Regarding the 
Asian IBS gender issue, Gwee et al
45 early pointed out lack of fe-
male predominance except the existed female predominance in 
Japan. Recent Asia IBS consensus also concludes no obvious fe-
male predominance existed in many Asia studies.
106 Tables 2-5 
provide the sex ratios among cited Asia studies. The ratios are 
widely variable ranging from equal to 2-fold of female predo-
minance. Even the same country may not obtain the similar gen-
der ratio among various reports, eg, Pakistan, Singapore, China 
and Korea, respectively. Accordingly, the female predominance 
looks to be commonly existed in Near East, Bangladesh, 
Southeast Asia, China, Japan and finally some but not all Korea 
studies, whereas the remaining countries just show similar or di-
verse ratio. With regard to the used criteria, a Korea study in-
dicates that female subjects showed a higher prevalence than male 
subjects under Rome III but not under Rome II criteria.
95 
Summarized together, the IBS female predominance is not 
uniquely existed among all Asia countries. 
Subtypes of IBS in Asia
The IBS subtypes are mainly divided according to the bowel 
movement (BM) frequency and stool consistency of the present-
ing subjects. Consequently, it looks important to know what is the 
so-called normal bowel habit in the general population. Among 
the Asia countries, many studies already provide the BM para-
meters. For instance, subjects with non-complaint of lower abdo-Asia IBS Prevalence 
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Table 6. Percentile Distribution of Reported Subtypes in Subjects With Irritable Bowel Syndrome
                    Criteria D-IBS C-IBS A (M)-IBS U-IBS 
Study Country Sample
                            size (%) (%) (%) (%)
Western and Latin
America countries
Hungin
40 2003 8 European  41,984
a Rome II 21.0 16.0 63.0          -
  countries
Vandvik
19 2006 Norway   4,622
a Rome II 23.0 24.0 53.0          -
Ersryd
49 2007 Sweden      249 Rome II  36.5 18.1 45.4          -
Rome III 39.0 31.0 63.0 23.7
Hillilä
14 2004 Finland   3,650
a Manning X2 41.2 22.7 NM NM
Manning X3 47.6 18.7 NM NM
Rome I 53.9 21.5 NM          -
Rome II 56.5 16.3 NM          -
Jones
53 1992  UK   1,620
a Manning 58.0 48.0 27.0 (Both) 21.0 (Neither)
Wilson
54 2004  UK   4,807
a Rome II 25.4 24.1 46.7          -
Dapoigny
56 2004  France 20,000
a Rome II 36.0 29.0 31.0          -
Katsinelos
59 2009  Greece   2,397
a Rome II 36.5 44.2 19.3          -
Andrews
25 2005 USA 25,986
a Rome II 53.0 19.7 25.8          -
Hungin
39 2005  USA   5,009
a Rome I 20.7 15.5 63.8          -
Rome II 22.6 16.1 61.3          -
Valerio-Ureña
64 2010  Mexico     459
a Rome II 28.2 50.0 21.8          -
Schmulson
113 2010 Mexico   1,021 Rome II 28.5 27.8 43.7          -
Asia countries
Sperber
26 2007 Israel   1,000
a Rome II 32.1 57.1 10.7          -
Rome III 16.1 36.6 47.3 NM
Celebi
27 2004  Turkey   1,766 Rome II 36.0 52.3 11.7          -
Yilmaz
77 2005  Turkey   3,000
a Rome II 48.1 38.9    - 13.0
Khoshkrood- Iran 18,180
a Rome III 18.0 52.0   8.0 NM
 Mansoori
101 2009 
Husain
28 2008  Pakistan      880 Rome II 29.3 50.4 20.3          -
Ghoshal
69 2008  India   4,500
a NM   4.0 39.0    - 57.0
Masud
83 2001  Bangladesh   2,426
a Rome II   0.8 16.0 19.2 63.9
Perveen
84 2009 Bangladesh   1,503
a Rome II 50.0 16.4   7.8 25.9
aCommunity based study.
X2, 2 diagnostic statements; X3, 3 diagnostic statements; IBS, irritable bowel syndrome; D-IBS, diarrhea predominant-IBS; C-IBS, constipation predominant-IBS; 
A-IBS, alternating-IBS; M-IBS, mixed-IBS; U-IBS, un-subtyped-IBS; NM, not mentioned.
men symptoms in India usually have the BM as 1-2 times/day.
69 
Over 90% people of Thailand and Singapore have the BM as 3 
times/day to 3 times/wk, while nearly 60% of them pass once 
daily.
38,70 Koreans also exhibit this BM pattern and 41% of them 
report once daily.
30 Meanwhile, 84% Chinese non-patient com-
m u n i t y  s u b j e c t s  r e p o r t  B M  o n c e  d a i l y  w i t h  a  m e a n  v a l u e  7  
times/wk. Besides, 90% of them pass formed soft stool, 77% fin-
ish it in the morning and only 3.8% show constipation and 1.1% 
as diarrhea, respectively.
111 It can be concluded that the BM 
ranging 3 times/day to 3 times/wk is acceptable as normal for 
most Asia people.    
Regarding the IBS subtypes, this subjective category remains 
difficult in clinical practice. Because the restrictive character of 
Rome II definition and alternating-IBS (A-IBS) being really un-
known as part of C- or D-IBS, most IBS are perhaps undiag-
nosed.
12,39 Surprisingly, even some A-IBS subjects think that 
their BM is normal despite the alternating expression.
24 There-
after, who such as physician or patient himself or what criteria 
should determine the subtype correctly? In addition, IBS sub-
types are likely depending upon heterogeneity in terms of eval-
uated population, gender, geographical location and criteria to 
define.
12,19,22,40,44,90,108,110 For example, the subtype correlation be-
tween Rome II and III has been poor because the apparently ex-
isted drawback in the categories of A-IBS, mixed-IBS and un-Full-Young Chang, et al
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Table 6. Continued
                    Criteria D-IBS C-IBS A (M)-IBS U-IBS 
Study Country Sample
                            size (%) (%) (%) (%)
Devanarayana
85 2010  Sri Lanka      427 Rome II 25.0 33.3 16.7 25.0
Rome III 26.7 26.7 33.3 13.3
Tan
36 2003 Malaysia      533 Rome I   7.1 77.4    - 15.5
Rajendra
86 2004  Malaysia      949
a Rome II 35.1 36.5 28.4    -
Gwee
24 2004  Singapore    2,276
a Rome II 12.8 51.0 NM    -
Kwan
87 2002  Hong Kong   1,000
a Rome II 27.0 17.0    - 56.0
Si
110 2004  China      662  Rome II 47.7 20.0 32.3    -
Xiong
35 2004  China   4178
a Rome II 74.1 15.1 10.8    -
Wang
89 2007  China   3,014 Rome II 38.2 33.2 28.7    -
Rome III 32.7 27.9   6.7  32.7
Dai
90 2008 China   1,147 Rome III 24.3 14.7 48.0 13.0
Wang
102 2009 China   3,014 Rome III 32.7 27.9   6.7 32.7
Zhao
92 2010 China 16,091
a Rome II 37.7 24.9 37.4    -
Kim
30 2005 Korea   1,717 Rome α 22.5 24.5    - 52.0
Han
32 2006 Korea   1,066
a Rome II 32.8 24.3 42.9    -
Son
94 2009 Korea      405 Rome II 26.9 34.5 38.8    -
Park
95 2010 Korea   1,009
a Rome II 27.2 37.0 25.9   9.9
Rome III 29.7 36.3 22.0 12.1
Noh
104 2010 Korea   2,388 Rome III 54.4 12.0 12.4 NM
Kumano
22 2004 Japan   4,000
a Rome II 31.1 41.0 27.9    -
Shiotani
96 2006 Japan   2,495 Rome II 43.7 47.8    -   8.6
Shinozaki
97 2008 Japan      633 Rome II 29.6 21.4 49.0    -
Hori
98 2009 Japan      181 Rome II 65.0 35.0    -    -
aCommunity based study.
X2, 2 diagnostic statements; X3, 3 diagnostic statements; IBS, irritable bowel syndrome; D-IBS, diarrhea predominant-IBS; C-IBS, constipation predominant-IBS; 
A-IBS, alternating-IBS; M-IBS, mixed-IBS; U-IBS, un-subtyped-IBS; NM, not mentioned.
subtyped-IBS, respectively.
49,90 Finally, a review indicates that 
USA population-based studies found similar distribution of 
C-IBS, D-IBS and A-IBS, whereas European studies showed ei-
ther C-IBS or A-IBS as the most prevalent subtypes. More inter-
estingly, primary care office-based studies showed A-IBS as the 
most prevalent group, while the specialist office-based studies 
found either C-IBS or D-IBS as the most frequently reported 
subtype.
12 It is likely the different attitude to acknowledge IBS 
between primary care and gastroenterologists. For example, not 
more than 50% of primary care physicians could reach the con-
sensus, while cultural differences in the description of key symp-
toms is responsible for this discrimination.
112 Table 6 depicts the 
percentile distribution of IBS subtypes in 12 Western and 28 
Asian countries. Among the developed countries, there is quite 
variable in the distribution of 3 main subtypes. Apart from 
Manning definition, it looks that the subtype proportions of 
C-IBS and D-IBS usually range 15%-55%, whereas this of 
A-IBS ranges higher as 20%-65%. The subtype correlation be-
tween Rome I and II is optimal but is not well existed between 
Rome II and III. For the Asian countries, the proportions of 
D-IBS distribute widely from 0.8% to 74.1%, C-IBS proportion 
ranges 12.0%-77.4%, whereas A-IBS appears less common with 
range 6.7%-49.0%. Of 8 Rome III criteria based studies showing 
subtypes, 5 report unsubtyped-IBS with proportion ranged 
12.1%-32.7%. Apart a Korea study,
95 the subtype correlation be-
tween Rome II and III is poor as well as this of Western studies. 
Summarized together, IBS subtype proportions are very variable 
among the Asia studies. It is likely to mean that the clear and pre-
cise differentiation of various subtypes to fit BM stool form and 
occupied duration remains very subjective both for the patients 
and physicians themselves.    
In conclusions, current Asia IBS prevalence is at least equal 
to the Western countries. Female predominant prevalence in 
Asia is common but not uniquely existed, while the proportions of 
IBS subtypes in Asia are too variable to find a rule.Asia IBS Prevalence 
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